ROBINS CHAD M

ADPT CEO Chad M Robins sold 120,595 shares for $1,766,839.09 in two transactions (Apr 6-8); stock down 27.5% from 52-week high.

CEO Chad M Robins executed 2 separate sales totaling 120,595 shares for $1,766,839.09 at blended average price $14.65, reducing his holdings by 5.2% from 2,301,113 to 2,180,518 shares. The stock is currently trading at $14.84, down 27.5% from its 52-week high of $20.46 and down 7.0% over the past 90 days. His same-ticker history shows 5 prior sales at ADPT, most recently on 2026-03-11, with measurable 30-day returns of -8.3%, -4.4%, and -8.8% on three of them; none of his ADPT sales have yet shown measurable 90-day outcomes. Across his broader cross-ticker track record (20 prior sells), his 90-day well-timed rate is 23.08%, meaning only about one-quarter of his historical sales have been followed by declines. The valuation remains stretched with a P/E of 114.15 despite the company returning to profitability (net income $9,546,000 on revenue of $93,973,000 in the latest quarter) and reporting strong annual revenue growth of 54.8%.

CEO Chad Robins sold 470,167 shares (470.2K shares) of ADPT for $6,192,099.39 ($6.2M) on 2026-03-11 at $13.17, reducing holdings by 17.0%.

CEO and Chairman Chad Robins executed 2 separate sales totaling 470,167 shares (470.2K shares) for $6,192,099.39 ($6.2M) at $13.17 per share, reducing his post-transaction holdings from 2,771,280 shares to 2,301,113 shares—a 17.0% reduction in stake. The sales occurred as the stock trades at -35.6% from its 52-week high of $20.46 and has declined 15.7% over the past 30 days and 14.7% over 90 days. This elevated sales activity—following 5 prior sells at ADPT within the past two weeks—occurs at a depressed price point relative to recent history. The company maintains a P/E of 101.31 despite positive near-term fundamentals (revenue $93,973,000.00 with +54.8% annual growth and net income $9,546,000.00), though it remains unprofitable on a full-year basis, suggesting valuation tension.

CEO Chad M Robins sold 524,998 shares (21.3% of holdings) at $15.85 avg over 4 sales for $8.3M

Chad M Robins, CEO and Chairman, executed 4 separate sales totaling 524,998 shares for $8,320,613.24 between February 27 and March 3, 2026, reducing his holdings from 2,459,245 shares to 1,934,247 shares. The sales occurred at an average price of $15.85, while the stock now trades at $16.08—indicating minimal downside on the executed transactions themselves. However, ADPT's 30-day price decline of -13.1% and 90-day decline of -6.1% from the 52-week high of $20.46 suggest the stock has faced broader weakness; the CEO's sales during this downturn merit scrutiny. His prior trades at ADPT show mixed timing outcomes: 2 of 3 measurable 90-day periods exhibited negative returns (well-timed sells on 2025-12-01 and 2025-11-26), but this most recent filing's timing cannot yet be assessed. The company's fundamentals present tension: strong revenue growth of +54.8% year-over-year and a recent quarter revenue of $93,973,000.00 with net income of $9,546,000.00, yet the full fiscal year remains unprofitable and the P/E of 123.69 reflects a stretched valuation for a company still loss-making on annual basis.

ADPT CEO Chad Robins sold 124,998 shares at $18.44; still holds 2,459,245 shares post-sale.

Chad Robins, CEO and Chairman of Adaptive Biotechnologies, sold 124,998 shares at $18.44 on 2026-02-02 for a total value of $2,304,963.12, reducing his holdings by approximately 4.8%. The sale occurred near the 52-week high ($20.46), with the stock currently at $17.30, down 15.4% from peak. His prior trades at ADPT show a mixed pattern: a 2026-01-05 sell gained 11.0% over 30 days, while three recent sales in November and December declined 15.1%, 14.3%, and 15.1% respectively over their 30-day windows. His cross-ticker track record (14 prior sales across all stocks) shows 0% well-timed execution at the 90-day horizon, with an average 90-day return of +19.3% after selling—indicating his sales typically precede subsequent stock gains. The company remains unprofitable on a full-year basis despite recent quarterly profitability ($9.5M net income in the latest quarter) and modest 5.1% annual revenue growth ($94.0M quarterly revenue). The CEO maintains a substantial 2.46M-share position, representing material ongoing exposure to the company.

CEO Chad Robins sells 124,998 shares of ADPT at $15.59; retains 2,584,243 shares. Stock now at $16.73 (+11.9% in 30d).

Chad M Robins, CEO and Chairman, sold 124,998 shares at $15.59 on 2026-01-05, reducing his holdings by 4.6% to 2,584,243 shares remaining. The stock has appreciated to $16.73 since the sale, marking an 11.9% gain over 30 days and 6.9% over 90 days. His track record across other tickers shows 13 prior sells with a 0.00% well-timed rate at 90 days (average 90d return +19.3%), meaning his cross-ticker sales have typically been followed by stock appreciation. At ADPT specifically, his prior five sales cluster in November-December 2025, with the two most recent sales (December 1 and November 26) showing negative 30-day returns of -14.3% and -15.1% respectively. The disparity between his historically poorly-timed cross-ticker sales and the recent positive price action post-sale warrants attention to whether this transaction reflects strategic positioning or routine capital allocation.

CEO Chad Robins sold 160,734 shares (5.6% of holdings) for $3.1M across 2 transactions at avg $19.10

CEO Chad Robins executed 2 separate sales totaling 160,734 shares for $3,070,746.60, reducing his stake from 2.87M to 2.71M shares. The sales occurred at $19.68 (35,736 shares on 2025-11-26) and $18.94 (124,998 shares on 2025-12-01), blended average $19.10, near the company's 52-week high of $20.46 and above the current price of $18.84. At ADPT specifically, Robins' prior 2 measurable sales (March 2025) yielded 90-day returns of -2.2% and +30.6%—a 0% well-timed rate—suggesting his recent timing decisions at this ticker have not consistently preceded price declines. His cross-ticker track record shows 11 prior sells with a 0.00% 90-day well-timed rate, meaning those sales were followed by stock gains rather than declines. The company posted $94.0M in revenue for the latest quarter with $9.5M net income, but remains unprofitable on a full-year basis despite +5.1% annual revenue growth, signaling operational pressure amid a $2.9B market cap.

CEO Chad Robins sold 89,265 shares at avg $14.73 for $1.3M across 3 days (Nov 10–12), reducing stake to 2.87M shares.

Chad Robins, CEO and Chairman of Adaptive Biotechnologies, executed three separate sales totaling 89,265 shares for $1,315,179.62 between November 10–12, 2025, at prices ranging from $14.57 to $15.00 and a blended average of $14.73. His holdings fell from 2.96M to 2.87M shares, a reduction of 3.0%. The sales occurred near the 52-week high ($17.83) with the stock currently at $14.50 (down 6.4% over 30 days but up 12.2% over 90 days). Robins' prior trades at Adaptive Biotechnologies show no well-timed sells at the 90-day mark: five prior sales in 2025 resulted in average 90-day returns of +30.6%, +42.4%, +42.2%, +7.7%, and +10.6%—meaning the stock rose after each sale. His cross-ticker track record shows a similar pattern, with an average 90-day return of +19.3% after sells and a 0.00% well-timed rate. The company's fundamentals remain mixed: latest quarterly revenue was $93,973,000, net income $9,546,000, with annual revenue growth of +5.1%, but the company posted a net loss over the most recent full fiscal year.

CEO Chad Robins sells 219,569 shares (6.9% of holdings) for $1,600,416.95 across 3 transactions at ADPT

Chad M Robins, CEO and Chairman of Adaptive Biotechnologies, executed 3 separate sales totaling 219,569 shares for $1,600,416.95 on March 5–6, 2025, reducing his holdings from 3,178,818 to 2,959,249 shares. The blended average sale price of $7.29 sits below the current price of $7.77 and well below the 52-week high of $8.52. The company reported negative net income of $-32,071,000.00 in its latest quarter and remains unprofitable on an annual basis, despite 5.1% annual revenue growth. Robins' prior trades at ADPT—five sells executed within days of this filing (Feb 13–20, 2025)—and his cross-ticker history of 5 prior sells establish a pattern of recent, sustained liquidation activity at the stock. These sequential open-market sales by the CEO during a period of continued operating losses warrant monitoring of any announcements or earnings revisions that may signal cash position or confidence adjustments.

ADPT CEO Robins sold 285,187 shares (10.0% of holdings) at $8.45–$8.46, raising $2.4M over 2 days as stock near 52-week high.

Chad M Robins, CEO and Chairman, executed 2 separate sales totaling 285,187 shares for $2,410,699.88 on 2025-02-19 and 2025-02-20 at an blended average price of $8.45, reducing his holdings by 10.0%. The sales occurred as the stock traded within 2.9% of its 52-week high of $8.52 and 30-day change is +3.2%, showing recent upward momentum. The company is unprofitable with a full-year net income of $-32,071,000.00 and annual revenue growth of -8.1%, creating a backdrop where the CEO's decision to liquidate a material portion of his position warrants scrutiny. His same-ticker history shows 3 prior sells within the past week (2025-02-13, 2025-02-14, 2025-02-18), establishing a pattern of consecutive discretionary sales rather than an isolated transaction.

CEO Robins sells 470,368 shares over 3 days at avg $8.47; holdings drop 15.4% to 2,576,701 shares

ADPT CEO Chad M. Robins executed three separate sales totaling 470,368 shares for $3,985,753.94 across February 13–18, 2025, reducing his holdings by 15.4% to 2,576,701 shares. The sales occurred at prices ($8.44–$8.50) near the stock's 52-week high of $8.52 and well above the current price of $8.27, suggesting execution during a period of relative strength. The company's fundamentals remain challenged: net income is negative at $-32,071,000.00, annual revenue declined 8.1%, and cash burn is evident, yet the stock has appreciated 21.4% over 30 days and 87.1% over 90 days from depressed levels. The scale and discretionary nature of this multi-transaction disposition merit scrutiny regarding leadership's confidence in the recovery trajectory.